Navigation Links
Rapamycin Optimized in 100 Liter Fermentor Using BioCommand Control Strategys


Researchers in New Brunswick Scientific's in-house labs have developed a unique control strategy to achieve high antibiotic expression levels in a pilot-scale fermentation process of Streptomyces hygroscopicus. Using the BioFlo 6000 fermentor's on-line controller with touchscreen interface augmented by the powerful supervisory capabilities of AFSBioCommand software, scientists were successful in optimizing the culture environment for rapamycin production. Harvested dry cell weight recovered from the 100 liter fermentor was over 25 grams/L; intracellular rapamycin production was over 110 milligrams/L; and fermentation time was reduced by almost a day to 120 hours.


Introduction
Streptomyces expresses a variety of secondary metabolites, such as rapamycin, which are used in medical and biological applications. During fermentation, dense mycelia are produced, which are highly variable in phenotype and especially susceptible to changing conditions during cultivation. Formation of secondary metabolites is usually favored by sub-optimal cell growth conditions. Nutrient transfer problems can restrict the metabolism of the culture, and a high oxygen transfer rate (OTR) is always required. Therefore, it was necessary to develop a fermentation protocol which allowed for initial cell growth to a sufficient density as to facilitate the production of large quantities of the antibiotic, while preventing the culture from becoming so dense as to interfere with its ability to obtain vital nutrients and oxygen for the production of rapamycin.


Materials and Methods
Seed inoculum of Streptomyces hygroscopicus NBS-9746, selected from ATCC 29253 cell strain, was cultured in an Innova 4300 incubator shaker, then transferred to a 10 L BioFlo IV bench fermentor, and fina
'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. Optimized Imaging of Protein Gels Stained with Coomassie Brilliant Blue Dye
2. Eagle Eye Optical Filter Optimized for Imaging Silver-Stained Gels
3. Optimized Dengue RT-PCR
4. P. pastoris Fermentation using a BioFlo 110 Benchtop Fermentor
5. E. coli Fermentation Using a BioFlo 110 Bench-Top Fermentor
6. An Easy-to-Use Research Fermentor/Bioreactor
7. Fundamentals of Fermentation: Techniques For Benchtop Fermentors
8. Low Abundance cDNA Cloned Using Stratagenes Human Universal cDNA Library
9. Oil-Free PCR Using the Hot Top Assembly
10. Functional Cloning Using ViraPort Retroviral cDNA Expression Libraries
11. Signal Transduction Reporting Systems Using Cis-Acting Enhancer Elements
Post Your Comments:
(Date:5/5/2015)... AVIV, Israel , May 5, 2015 /PRNewswire/ ... the Company was approved to continue trading on ... OTCQB Marketplace allows for a ... electronic broker-dealers. Investors can have real-time quotes and ... The OTCQB Marketplace includes U.S. ...
(Date:5/5/2015)... 5, 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") ... , President and Chief Executive Officer, will present ... DATE:  Thursday, May 7, 2015     TIME:  11:30 am ... > click the red "register/ watch presentations" button ... online event where investors are invited to ask ...
(Date:5/5/2015)... DUBLIN , May 05, 2015 Research ... announced the addition of the "Clinical Laboratory, ... and Forecast 2015 to 2019 - Global Version" ... technical developments especially in the area of molecular ... dynamic, growing and evolving world market that is ...
(Date:5/5/2015)... May 5, 2015   Tocagen Inc. , ... David R. Parkinson , M.D., a venture partner ... to the board of directors of Tocagen. Dr. ... in oncology clinical development, including leading clinical activities ... approvals of the cancer therapeutics Gleevec®, Femara®, Zometa®, ...
Breaking Biology Technology:Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7 2Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 3Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 4
... VANCOUVER , July 30 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. ... quarter ended June 30, 2010 . , ... "We are pleased to report continued quarter over quarter ... Products," said Dr. William Hunter , President and CEO of Angiotech. ...
... lend materials new characteristics are generally complicated and therefore ... to astonishment when scientists report on new methods which ... they use economically priced starting materials but also do ... framework made of polystyrene This is exactly ...
... Inc. (Nasdaq: MYL ) today announced that it intends to ... senior notes through a reopening of its Senior Notes due 2020, ... as additional notes under an existing indenture under which Mylan issued ... 2020 on May 19, 2010 . The notes to be ...
Cached Biology Technology:Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 2Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 3Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 4Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 5Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 6Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 7Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 8Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 9Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 10Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 11Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 12Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 13Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 14Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 15Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 16Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 17Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 18Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 19Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 20Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 21Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 22Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 23Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 24Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 25Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 26Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 27Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 28Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 29Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 30Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 31Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 32Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 33Empa grows 'sea urchin'-shaped structures 2Mylan Announces Proposed Add-On Private Placement of its Senior Notes Due 2020 2Mylan Announces Proposed Add-On Private Placement of its Senior Notes Due 2020 3
(Date:5/6/2015)... TEL AVIV, Israel , May 6, 2015 /PRNewswire/ ... the world,s most established helmet producer, announced today that ... LifeBEAM Smart Helmet, the world,s first bio-sensing cycling helmet ... will be released in two new colors in order ... demand for the product. In addition, LifeBEAM and Lazer ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, reminds investors ... Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA ... 5-7, 2015. The three-day conference is organized ... is speaking in is themed Global Fraud: Where is ...
(Date:4/27/2015)... 2015  For more than four decades, AUVSI,s ... the premier worldwide event for the unmanned land, sea, ... event for any local, national, or trade news organization ... markets and current applications of unmanned technologies. The conference ... $48 billion industry, and how it will soon impact ...
Breaking Biology News(10 mins):LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5
... in hairy nanoparticles can cheaply and conveniently measure mercury, ... in fluids. Researchers at the Swiss Federal ... of Michigan found that their new method can measure ... at unprecedentedly small concentrations. The system, which could test ...
... Scientists at Mount Sinai School of Medicine have discovered ... properties and resistance to chemotherapy, and participate in tumor ... new tests for early cancer diagnosis, prognostic tests, and ... . Resistance to chemotherapy is a ...
... the German government to transform the energy system and phase ... but much remains to be done. During the course of ... expanded not only through costly offshore facilities, but onshore ... to be tapped, such as in the low mountain ranges," ...
Cached Biology News:Measuring mercury levels: Nano-velcro detects water-borne toxic metals 2Measuring mercury levels: Nano-velcro detects water-borne toxic metals 3Researchers reveal a chemo-resistant cancer stem cell as cancer's 'Achilles' heel' 2More accurate wind energy forecasts 2More accurate wind energy forecasts 3
... Not treated (or medium binding) polystyrene ... binds biomolecules through passive interactions,• Is ... large molecules, such as antibodies, that ... interact with the surface,• Binding capacity ...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. Material: polystyrene flat ...
... • Reusable, press-to-seal gasket and cover ... and disassembled for hybridizing and imaging thick ... with up to a 13 mm diameter. ... Minimize specimen handling, eliminate evaporation and leaking ...
Comp Dim: chamber diam. depth 20 2.8 mm chamber maximum volume 720 μL...
Biology Products: